In this podcast episode, Charles Rudin, MD, PhD, and Mark A. Socinski, MD, discuss current gaps and clinical needs for patients with relapsed ES-SCLC, and the evolving role of B7-H3–directed antibody–drug conjugates in the management of patients with ES-SCLC, including:Clinical needs for relapsed ES-SCLCScientific rationale for targeting B7-H3 and other tumor-associated antigens in SCLCADCs, T-cell engagers, chemotherapy-based approaches, maintenance strategies, and ongoing clinical trials for ES-SCLCRecent efficacy and safety data for B7-H3–directed ADCs in ES-SCLC, including I-DXdPersonalization of care of patients with SCLC, including patient-specific factors influencing treatmentCase discussion of a patient with ES-SCLC requiring optimal next best treatmentImportance of enrolling patients in ongoing trials of investigational agents for patients with ES-SCLCPresenters:Charles Rudin, MD, PhDCancer Center DirectorMemorial Sloan Kettering Cancer CenterNew York, New YorkMark A. Socinski, MDExecutive Medical DirectorAdventHealth Cancer InstituteOrlando, FloridaLink to full program:https://bit.ly/3UBEeYz Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related